BIOMAT Database Logo BIOMAT Database Logo

Regulation of c-myc expression by IFN in Burkitt's lymphoma cells. 1985

T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D015088 2',5'-Oligoadenylate Synthetase An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions. 2',5'-Oligoadenylate Polymerase,2-5A Synthetase,(2'-5')An Polymerase,2',5'-Oligo(A) Polymerase,2',5'-Oligo(A) Synthetase,2,5 Oligoadenylate Polymerase,2,5 Oligoadenylate Synthetase,ATP-(2'-5')oligo(A)adenylyltransferase,2',5' Oligoadenylate Polymerase,2',5' Oligoadenylate Synthetase,Oligoadenylate Polymerase, 2,5,Oligoadenylate Synthetase, 2,5,Polymerase, 2',5'-Oligoadenylate,Polymerase, 2,5 Oligoadenylate,Synthetase, 2',5'-Oligoadenylate,Synthetase, 2,5 Oligoadenylate

Related Publications

T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
c-myc Suppression in Burkitt's lymphoma cells.
January 2002, Biochemical and biophysical research communications,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Expression of normal and translocated c-myc alleles in Burkitt's lymphoma cells: evidence for different regulation.
July 1989, The EMBO journal,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
April 2000, Molecular and cellular biology,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
c-myc hypermutation in Burkitt's lymphoma.
December 1992, Leukemia & lymphoma,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma.
August 1993, Journal of clinical pathology,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
July 2003, Proceedings of the National Academy of Sciences of the United States of America,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives.
December 1985, The EMBO journal,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
September 2015, Oncotarget,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
March 1996, The Journal of biological chemistry,
T Salehzada, and J M Blanchard, and N Mechti, and M Piechaczyk, and C Dani, and P Jeanteur, and B Lebleu
Regulation of expression of c-fos and c-myc in rat lymphoma Nb-2 cells.
August 1987, Biochimica et biophysica acta,
Copied contents to your clipboard!